12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Elotuzumab: Additional Phase II data

Additional data from an open-label Phase II trial in 73 patients with previously treated MM showed that 20 mg/kg elotuzumab plus Revlimid lenalidomide and low-dose dexamethasone led to a median PFS of 18.6 months and an ORR of 76%. In patients receiving 10 mg/kg elotuzumab plus Revlimid and low-dose dexamethasone, median PFS has not been reached after 20.8 months of follow-up and the ORR was...

Read the full 315 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >